Toumai® Robot Enables Three Telesurgeries Across 5,000 km in a Single Day

Shanghai & Kashgar, China, 25 August, 2025 — Three leading surgeons in Shanghai used the same Toumai^® Endoscopic Surgical Robot (Toumai^®) to consecutively perform telesurgeries for three patients in Kashgar, over 5,000 kilometers away. This marks a world first: multiple experts successfully performed high-complexity, cross-specialty telesurgeries using a single surgical robot. It highlights Toumai®’s stability and adaptability under continuous telesurgery operation. 

The telesurgeries were conducted and live streamed at the Toumai^® DeepNet™ Telesurgery Smart Connection Center of MicroPort^® MedBot™.

Highlights of the Day

• Radical Prostatectomy: Prof. Jiahua Pan, Director of Urology at Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, demonstrated Toumai^®’s articulating precision and 3D vision to complete nerve-sparing dissection in a complex prostate cancer case.
• Left Hemicolectomy for Colon Cancer: Prof. Ren Zhao, Vice President and Chief of General Surgery at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, successfully managed dense intra-abdominal adhesions and a large tumor mass, leveraging Toumai^®’s stable instrument reach to achieve full oncologic resection.
• Single-Port Total Hysterectomy with Bilateral Salpingo-Oophorectomy: Prof. Guizhu Wu, Director of Gynecology at Shanghai First Maternity and Infant Hospital, utilized Toumai^®’s multi-arm single-port system to perform delicate dissection and suturing in the narrow pelvic cavity.

Experts speaking during the live broadcast emphasized that these cases were not only a technological milestone but also a practical model for bringing advanced medical surgical expertise closer to patients in remote areas.

Toumai^® has gained broad clinical adoption across urology, general surgery, thoracic surgery, gynecology, pediatric surgery, and thyroid and breast surgery. Looking ahead, the ongoing use of Toumai^® is expected to further support clinical practice in underserved regions, while demonstrating the potential of telesurgery to improve patient access and outcomes worldwide.  

About MicroPort^® MedBot™   

Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort^® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort^®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort^® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.

More information is available at: www.medbotsurgical.com/en